SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 68 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,523,225 | -30.0% | 3,617,302 | +1.0% | 0.00% | -50.0% |
| Q2 2023 | $74,985,284 | +1.5% | 3,582,670 | +2.4% | 0.00% | 0.0% |
| Q1 2023 | $73,858,436 | -13.7% | 3,497,085 | +4.0% | 0.00% | 0.0% |
| Q4 2022 | $85,599,802 | +27.1% | 3,363,450 | +20.0% | 0.00% | 0.0% |
| Q3 2022 | $67,339,000 | +25.9% | 2,802,299 | +0.8% | 0.00% | 0.0% |
| Q2 2022 | $53,504,000 | +26.6% | 2,780,903 | +14.3% | 0.00% | +100.0% |
| Q1 2022 | $42,277,000 | -17.4% | 2,432,438 | +4.1% | 0.00% | 0.0% |
| Q4 2021 | $51,165,000 | +23.4% | 2,337,370 | +7.7% | 0.00% | 0.0% |
| Q3 2021 | $41,457,000 | +14.5% | 2,169,406 | +2.9% | 0.00% | 0.0% |
| Q2 2021 | $36,207,000 | -21.8% | 2,108,748 | +1.8% | 0.00% | 0.0% |
| Q1 2021 | $46,307,000 | +12.4% | 2,070,948 | +11.8% | 0.00% | 0.0% |
| Q4 2020 | $41,185,000 | +99.7% | 1,851,833 | +32.5% | 0.00% | 0.0% |
| Q3 2020 | $20,620,000 | -2.9% | 1,397,085 | -2.5% | 0.00% | 0.0% |
| Q2 2020 | $21,230,000 | +79.4% | 1,432,540 | +32.8% | 0.00% | 0.0% |
| Q1 2020 | $11,834,000 | +26.0% | 1,078,728 | +0.9% | 0.00% | – |
| Q4 2019 | $9,391,000 | +17.3% | 1,069,587 | -0.2% | 0.00% | – |
| Q3 2019 | $8,009,000 | -16.4% | 1,072,148 | +4.2% | 0.00% | – |
| Q2 2019 | $9,581,000 | +92.4% | 1,029,150 | +8.5% | 0.00% | – |
| Q1 2019 | $4,979,000 | +31.9% | 948,389 | +11.8% | 0.00% | – |
| Q4 2018 | $3,776,000 | -36.5% | 848,642 | +15.2% | 0.00% | – |
| Q3 2018 | $5,951,000 | +11.1% | 736,604 | -3.5% | 0.00% | – |
| Q2 2018 | $5,356,000 | -49.4% | 762,940 | +2.6% | 0.00% | – |
| Q1 2018 | $10,586,000 | +74.9% | 743,944 | +7.7% | 0.00% | – |
| Q4 2017 | $6,052,000 | -14.3% | 690,882 | +14.4% | 0.00% | – |
| Q3 2017 | $7,064,000 | -1.4% | 603,779 | +17.8% | 0.00% | – |
| Q2 2017 | $7,161,000 | +27.3% | 512,624 | +25.1% | 0.00% | – |
| Q1 2017 | $5,624,000 | +100.9% | 409,924 | +5.0% | 0.00% | – |
| Q4 2016 | $2,799,000 | -37.0% | 390,402 | +33.3% | 0.00% | – |
| Q3 2016 | $4,441,000 | +165.3% | 292,924 | +72.4% | 0.00% | – |
| Q2 2016 | $1,674,000 | – | 169,901 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |